Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide

BACKGROUND: Glioblastoma is an aggressive form of brain cancer. Approximately five in 100 people with glioblastoma survive for five years past diagnosis. Glioblastomas that have a particular modification to their DNA (called methylation) in a particular region (the O(6)‐methylguanine–DNA methyltrans...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cochrane Database Syst Rev
Autors principals: McAleenan, Alexandra, Kelly, Claire, Spiga, Francesca, Kernohan, Ashleigh, Cheng, Hung-Yuan, Dawson, Sarah, Schmidt, Lena, Robinson, Tomos, Brandner, Sebastian, Faulkner, Claire L, Wragg, Christopher, Jefferies, Sarah, Howell, Amy, Vale, Luke, Higgins, Julian P T, Kurian, Kathreena M
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Ltd 2021
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078495/
https://ncbi.nlm.nih.gov/pubmed/33710615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013316.pub2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars